This appraisal has been suspended.
Empaglifozin is already recommended for people with type 2 diabetes (TA336) and the population for which this additional appraisal would be aimed at (poorly controlled diabetes plus cardiovascular risk) is already included in the population previously appraised. Cardiovascular endpoints are already part of the case for cost effectiveness of empagliflozin as established in TA336, therefore published NICE guidance already covers indication.
| Status | Suspended |
| Process | STA pre-2018 |
| ID number | 1037 |
Project Team
| Project lead | Jeremy Powell |
Email enquiries
- If you have any queries please email TACommB@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 01 February 2018 | Suspended. This appraisal has been suspended. Empaglifozin is already recommended for people with type 2 diabetes (TA336) and the population for which this additional appraisal would be aimed at (poorly controlled diabetes plus cardiovascular risk) is already included in the population previously appraised. Cardiovascular endpoints are already part of the case for cost effectiveness of empagliflozin as established in TA336, therefore published NICE guidance already covers indication. |
| 21 April 2017 | Referral |
| 21 April 2017 | In progress. Topic referred |
| 22 November 2016 - 20 December 2016 | Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators |
For further information on how we develop guidance, please see our page about NICE technology appraisal guidance